



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/523,964

02/07/2005

Mitchell Avery

11636N/021304

3982

32885 7590 11/07/2007
STITES & HARBISON PLLC
424 CHURCH STREET
SUITE 1800
NASHVILLE, TN 37219-2376

EXAMINER

CHANDRAKUMAR, NIZAL S

ART UNIT

PAPER NUMBER

1625

MAIL DATE

DELIVERY MODE

11/07/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/523,964	Applicant(s) AVERY ET AL.	
	Examiner Nizal S. Chandrakumar	Art Unit 1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 15 October 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1 and 9-16 is/are pending in the application.
- 4a) Of the above claim(s) 12-16 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,9 and 10 is/are rejected.
- 7) ☒ Claim(s) 11 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

This application filed 02/07/2005 is a 371 of PCT/US03/24938 08/07/2003 which claims benefit of 60/401,664 08/07/2002.

Claims 1, 9-11 are pending.

Election/Restrictions

1. Applicant's election with traverse of Group I, claims 1, 9-11, in the reply filed on 10/15/2007 is acknowledged. The traversal is on the ground(s) that the element shown in the prior art is significantly distinguishable from the claimed compounds. This is not found persuasive because the instantly claimed compounds are analogs and are derivatives of well known compounds in the prior art, including the cited reference (see below rejections under *102*).

The requirement is still deemed proper and is therefore made FINAL.

2. Claims 12-16 withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 10/15/2007.

3. This application contains claim 12-16 drawn to an invention nonelected with traverse in Paper No. 10/15/2007. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Claim Rejections - 35 USC § 112

5. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1625

6. Claims 1, 9-10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
7. The definition of variable R15 is vague. It is not clear what is position of attachment of methoxybenzene containing fragment.
8. The definition of R16 is vague and indefinite because it is not clear what the substituent are included are excluded. For example, it is unclear what alkyl, aryl groups the applicant is seeking protection for.
9. Claims 9 and 10 recite the limitation "HET". There is insufficient antecedent basis for this limitation in the claim.
10. The claims are drawn to 'prodrugs' without particularly pointing out what the prodrugs are.

Claim Rejections - 35 USC § 112

11. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 9-10 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a limited number of compounds of the formula, does not reasonably provide enablement for the plurality of possible structures claimed. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims. The formula encompasses independently varying groups leading a large number of different structures. For example, the groups R15 are defined to be present in all the possible positions of the phenyl groups while the specification is enabling for these substituents to be present at the 4-yl position only. In addition, it is not seen wherein the specification, enablement is present for R16 being other than H. As such, the specification does not enable any person skilled in the art to which it pertains,

Art Unit: 1625

or with which is most nearly connected, to practice the invention commensurate in scope of these claims.

Enablement is considered in view of the Wands factors (MPEP 2164.01 (a)). These include: (1) breadth of the claims; (2) nature of the invention; (3) state of the prior art; (4) amount of direction provided by the inventor; (5) the level of predictability in the art; (6) the existence of working examples; (7) quantity of experimentation needed to make or use the invention based on the content of the disclosure; and (8) relative skill in the art.

All of the factors have been considered with regard to the claim, with the most relevant factors discussed below:

The breadth of claims: The presence of undefined groups such as alkyl, aryl etc in R16 as well as the unknown position of attachment of R15 and R16 in addition to the undisclosed prodrugs render the number of conceivable structures large one that is not supported by the specification.

The level of the skill in the art: The level of skill in the art is high. However, due to the unpredictability in the art of organic and medicinal chemistry, it is noted that each embodiment of the invention is required to be individually assessed for viability.

The amount of direction provided by the inventor and the presence or absence of working examples: The guidance and working examples provided in the specification is limited.

The preparation of R16 substituted compounds depend on the availability of R16 substituted para bromo phenyl acetic acids (see page 32 of the specification). The specification does not provide citations (commercial or literature) for procuring the starting materials usable that could substitute for the lack of working examples with respect to this substitutions. Likewise the preparation of R15 substituted compounds depends on the availability of bromo (or other substitutions susceptible to Pd insertion) substituted phenyl acetic acids. This limits the what is enabled with respect to the R15 amino substitution. In addition, the crucial introduction of the amino group by Buchwald type transformation

limits the theoretically possible R16 groups. The specification does not provide citations (commercial or literature) for procuring the starting materials usable that could substitute for the lack of working examples with respect to this substitutions.

It is not seen wherein the specification discloses the preparation and function of the prodrugs of the compounds of the formula.

The state and the predictability of the art: The state of the art is unpredictable as to functional group compatibility during many chemical transformations, in spite of major advances in protecting group strategies in synthesis. The unpredictability of the success of Buchwald chemistry in multi-functional substrate is well known. The existence of such art-recognized limitations establishes that the contemporary knowledge in the art of organic synthesis would prevent one of ordinary skill in the art from accepting any claimed process described for seemingly related molecules such as the ones present in the specification, on its face as universally applicable for making all structures of compounds of the formula.

The quantity of experimentation: Given the limited Examples provided in the specification, in order to utilize the invention as claimed, the skilled artisan would be presented with an unpredictable amount of experimentation. Consequently, a burdensome amount of research would be required by one of ordinary skill in the art to bridge this gap. The instant disclosure is broad and generic. Further, based on the disclosure with respect to the biological activity of the compounds of the formula, it is not clear what specific embodiments would be required in order for one of ordinary skill in the art at the time the invention was made to practice the instant invention commensurate in scope with the claims.

Genentech Inc. v. Novo Nordisk A/S (CA FC) 42 USPQ2d 1001, states, "a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion" and "[p]atent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable".

Claim Rejections - 35 USC § 102

12. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:


A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

13. Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Shao et al. (STN Accession Number: 1981:174809; Document Number: 94:174809; Yaoxue Xuebao (1980), 15(9), 538-47) who teach

RN 77316-78-0 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-(4-aminophenyl)-7-hydroxy- (9CI) (CA INDEX NAME)



corresponding to the compound of formula wherein R15 is amino and R16 is H.

Allowable Subject Matter

14. Claim 11 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nizal S. Chandrakumar whose telephone number is 571-272-6202. The examiner can normally be reached on 8.30 am - 5 pm Monday- Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached at 571-272-0867 or Primary Examiner D. Margaret Seaman can be reached at 571-272-0694. The fax phone number for the organization where this application or

Art Unit: 1625

proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Nizal S. Chandrakumar



D. MARGARET SEAMAN
PRIMARY EXAMINER